ARVINAS, INC. Amortization of Debt Issuance Costs
ARVINAS, INC. (ARVN) reported Amortization of Debt Issuance Costs of $7.21 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2021-03-01
- ARVINAS, INC. amortization of debt issuance costs for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- ARVINAS, INC. amortization of debt issuance costs for the quarter ending 2019-09-30 was $1.03K, a 66.66% decline year-over-year.
- ARVINAS, INC. amortization of debt issuance costs for the quarter ending 2019-06-30 was $3.09K, a 0.00% change year-over-year.
- ARVINAS, INC. amortization of debt issuance costs for the quarter ending 2019-03-31 was $3.09K, a 0.00% change year-over-year.
- ARVINAS, INC. amortization of debt issuance costs for fiscal 2019 was $7.21K, a 41.66% decline from fiscal 2018.
- ARVINAS, INC. amortization of debt issuance costs for fiscal 2018 was $12.36K, a 0.00% change from fiscal 2017.
- ARVINAS, INC. amortization of debt issuance costs for fiscal 2017 was $12.36K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.03K derived: sum of 2 quarters · filed 2021-03-01 | $4.12K derived: sum of 3 quarters · filed 2021-03-01 | $7.21K 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.12K derived: sum of 2 quarters · filed 2020-11-05 | $7.21K 10-Q · filed 2020-11-05 | $10.30K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $6.18K 10-Q · filed 2020-08-04 | $9.27K derived: sum of 3 quarters · filed 2021-03-01 | $12.36K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $3.09K 10-Q · filed 2020-04-28 | $6.18K derived: sum of 2 quarters · filed 2021-03-01 | $9.27K derived: sum of 3 quarters · filed 2021-03-01 | $12.36K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.09K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $6.18K derived: sum of 2 quarters · filed 2021-03-01 | $9.27K derived: sum of 3 quarters · filed 2021-03-01 | $12.36K 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $6.18K derived: sum of 2 quarters · filed 2019-11-04 | $9.27K 10-Q · filed 2019-11-04 | $12.36K derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $3.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $6.18K 10-Q · filed 2019-08-05 | $9.27K derived: sum of 3 quarters · filed 2019-08-05 | |
| 2018-03-31 | $3.09K 10-Q · filed 2019-05-09 | $6.18K derived: sum of 2 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $3.09K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $12.36K 10-K · filed 2019-03-26 | ||
| 2017-09-30 | $9.27K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |